J3L-MC-EZEB: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults with Elevated Lipoprotein(a)

The primary objective of this study is to evaluate the efficacy of **LY3819469** in reducing the percentage of elevated **Lipoprotein(a)** [Lp(a)] levels in adults, compared to a placebo. Elevated Lp(a) is a significant risk factor for cardiovascular diseases, and its reduction is clinically relevant as it may lower the risk of associated cardiovascular events. The study aims to determine whether LY3819469, administered as a solution for injection, is superior to placebo in achieving this reduction.

The clinical trial involves a total of **130 participants** diagnosed with **Lipoprotein Disorder**. The study population includes both male and female subjects, aged 40 years and older. Participants were selected based on specific criteria, including having an Lp(a) level of at least 175 nmol/L at screening and maintaining a stable dose of any lipid-lowering drugs or hormone therapy for a minimum of four weeks prior to screening. The trial includes individuals with a body mass index ranging from 18.5 to 40 kg/m². Lifestyle considerations such as diet and physical activity are not specified, but participants are required to adhere to any existing medication regimens. The trial does not involve a vulnerable population, and both genders are represented, with males agreeing to use highly effective contraception methods or females being not of childbearing potential.

The clinical trial is a **randomized**, **double-blind**, **placebo-controlled** study designed to evaluate the efficacy and safety of LY3819469 in adults with elevated **lipoprotein(a)** levels. The primary objective is to determine if LY3819469 is superior to placebo in reducing the percentage of lipoprotein(a) over a specified period. The trial involves administering LY3819469, a **synthetic siRNA**, as a **solution for injection** via the **subcutaneous** route. The study is expected to last until January 16, 2024, with recruitment having commenced on October 31, 2022.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age, lipoprotein(a) levels, and body mass index. The trial includes follow-up visits to monitor the participants' response to the treatment and any adverse effects. The end-of-study visit will assess the overall outcomes and safety of the intervention. The expected duration of participant involvement is approximately 20 weeks, with the possibility of early termination if adverse events occur or if the participant withdraws consent.

Inclusion criteria require participants to be at least 40 years old, have a lipoprotein(a) level of at least 175 nmol/L, and maintain stable doses of any lipid-lowering drugs or hormone therapy for at least four weeks prior to screening. Participants must also have a body mass index between 18.5 and 40 kg/m². Male participants must agree to use highly effective contraception methods, while female participants must not be of childbearing potential. The primary endpoint is the percent change from baseline in time-averaged lipoprotein(a) over days 60 to 180. The trial is categorized as a Phase II study, assessing a non-authorized investigational medicinal product to investigate safety and efficacy.

The clinical trial involves the administration of **LY3819469 sodium**, an experimental medication developed by Eli Lilly and Company Limited. This investigational product is formulated as a **solution for injection** and is classified as a synthetic small interfering RNA (siRNA). The medication is administered via the **subcutaneous route**. The dosing regimen for LY3819469 sodium includes a maximum daily dose of 400 mg, with a total maximum dose of 800 mg over a treatment period of up to 20 days. The primary objective of the trial is to evaluate the efficacy of LY3819469 in reducing elevated levels of lipoprotein(a) in adult participants.

In addition to the experimental treatment, a **placebo** is utilized as a comparator in this double-blind, placebo-controlled study. The placebo is designed to match LY3819469 in appearance and administration method, ensuring that neither the participants nor the investigators are aware of the treatment assignments. The placebo does not contain any active pharmaceutical ingredients and serves to provide a baseline for evaluating the efficacy and safety of the experimental medication. Compliance with the dosing schedule and administration is monitored throughout the trial to ensure adherence to the study protocol.

The efficacy of LY3819469 in the clinical trial will be assessed by evaluating the primary endpoint, which is the percent change from baseline in time-averaged **Lipoprotein(a)** (Lp(a)) levels over Days 60-180. This endpoint is designed to determine if LY3819469 is superior to placebo in reducing Lp(a) levels in adults with elevated Lp(a). The trial is a Phase 2, randomized, double-blind, placebo-controlled study, ensuring that the assessment of efficacy is conducted under rigorous conditions to minimize bias and ensure the reliability of the results. The measurement of Lp(a) levels will be conducted at specified time points, and the data collected will be analyzed to determine the efficacy of the investigational product compared to placebo. The trial's main objective is to establish the superiority of LY3819469 over placebo in achieving a significant reduction in Lp(a) levels, which is a critical factor in assessing the potential therapeutic benefit of the investigational product.